Physician profile
James Rybak
NPI 1801042700
$10,645.82
in general payments reported to CMS, 2019-2025
46 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what 83% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,986 · 2020: $511 · 2021: $1,383 · 2022: $1,064 · 2023: $935 · 2024: $1,427 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,527 · Travel and Lodging: $1,001 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.91 |
| Travel and Lodging | $1,001.12 |
| Education | $173.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $2,051.34 | 2021-2025 | Aquabeam System, Aquabeam Robotic System |
| Neotract INC. | $1,734.40 | 2019-2020 | |
| Astellas Pharma US INC | $866.65 | 2019-2025 | Xtandi, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $446.28 | 2019-2025 | |
| Janssen Biotech, INC. | $390.37 | 2019-2024 | Erleada, Akeega |
| Teleflex LLC | $352.63 | 2021-2024 | Urolift |
| Merck Sharp & Dohme LLC | $350.84 | 2020-2024 | Lynparza, Keytruda |
| Accord Healthcare, INC. | $349.53 | 2023-2024 | |
| Boston Scientific Corporation | $347.61 | 2019-2025 | Spaceoar Vue System - 10ml |
| Urogen Pharma, INC. | $342.98 | 2021-2025 | Jelmyto |
| Antares Pharma, INC. | $300.41 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $286.36 | 2023-2025 | Orgovyx, Gemtesa |
| Myriad Genetic Laboratories, INC. | $263.46 | 2021-2025 | Prolaris |
| Rochester Medical Corporation | $243.45 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $230.85 | 2019-2025 | Adstiladrin |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rybak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.